Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

August 4, 2017: By Jon Swedien
Mynosys Zepto disposable handpiece

Mynosys’ Zepto disposable handpiece

Mynosys has received a $1 million government grant to commercialize its Zepto capsulotomy system, the Fremont, California, company announced Aug. 1.

The National Eye Institute (NEI) of the National Institutes of Health (NIH) awarded Mynosys an SB1 Commercialization Readiness Program award, which is intended to support the transition of previously NIH-funded projects to the commercialization stage. Mynosys has received $5.3 million in total from the NIH’s Small Business Innovation Research program.

The Zepto, which received US 501(k) clearance in June, is designed to allow cataract surgeons to create automated, circular, exactly sized capsulotomies tailored to the individual patient.

The system is the first non-laser automated cataract capsulotomy device to gain US approval, but several others are expected to follow. The device received CE marking in December 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022